SARS-Cov-2 infection in cancer patients, susceptibility, outcome and careArticle Published on 2022-11-012022-11-15 Journal: The American journal of the medical sciences [Category] COVID19(2023년), SARS, 진단, [키워드] anti-cancer treatment antibody benefit Cancer Cancer patients cancers Care coronavirus COVID-19 COVID-19 pandemic doses Factor generate healthy hematologic impacted implication increased risk individuals Infection knowledge observation outcome Pandemics Patient patients Perception problem response to vaccination risk SARS-CoV-2 SARS-COV-2 infection shown susceptibility Vaccines virus [DOI] 10.1016/j.amjms.2022.05.017 PMC 바로가기
Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic reviewArticle Published on 2022-11-012022-11-15 Journal: British Journal of Cancer [Category] COVID19(2023년), SARS, 진단, [키워드] access acute respiratory syndrome Affect Antibody Response anticancer association B-cell benefit booster booster dose booster vaccination Booster vaccine Cancer Coronavirus-2 depleting dose doses Efficacy evaluated Evidence haematological malignancies immunological responses include induce Infection malignancies morbidity and mortality organ Patient patients Patients with cancer receive recent risk SARS-CoV-2 SARS-CoV-2 vaccination Seroconversion significantly increased solid cancer systematic narrative review systematic review therapy vaccination [DOI] 10.1038/s41416-022-01951-y PMC 바로가기
Systematic comparison of ranking aggregation methods for gene lists in experimental resultsArticle Published on 2022-10-312022-11-16 Journal: Bioinformatics [Category] COVID19(2023년), meta-analysis, SARS, [키워드] addition aggregation Algorithm Apoptosis automated Bacteria biological process Cancer Cell Characteristics code Consensus database dataset datasets disease downloaded Evaluating Features genomic data heterogeneity implementation implicated Inclusion information lack list of gene lung cancer Macrophage Meta-analysis noise level question reliability required resulting specific type Support the SARS-CoV-2 virus Variation was performed were used [DOI] 10.1093/bioinformatics/btac621 PMC 바로가기
Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case reportArticle Published on 2022-10-312022-11-15 Journal: Journal of Medical Case Reports [Category] 진단, [키워드] Administered Advanced basal cell carcinoma atezolizumab bladder Bladder cancer Cancer cancers carried Case report Cell Checkpoint inhibitor chemotherapeutic agent clinician Comorbidity Complete Compliance complication of COVID-19 cumulative Definitive disease dose female histology hospital increasingly indicated Infection inhibitor knowledge lymph nodes Metastasis metastatic Metastatic muscle-invasive bladder cancer Patient PD-L1 PD-L1 inhibitor. positive progressed Radiotherapy reached receiving Side effects smoking synchronous the patient therapy transurethral resection treated Treatment tumors [DOI] 10.1186/s13256-022-03634-x PMC 바로가기
Health influence of SARS-CoV-2 (COVID-19) on cancer: a reviewReview Published on 2022-10-252023-07-10 Journal: Acta biochimica et biophysica Sinica [Category] COVID19(2023년), [키워드] Cancer COVID-19 pathology SARS-CoV-2 Tumor [DOI] 10.3724/abbs.2022147 PMC 바로가기 [Article Type] Review
Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancerArticle Published on 2022-10-242023-07-10 Journal: Frontiers in Immunology [Category] COVID19(2023년), [키워드] Cancer COVID-19 memory B cells SARS-CoV-2 Vaccine [DOI] 10.3389/fimmu.2022.1028246 PMC 바로가기
Autoantibodies – enemies, and/or potential allies?Article Published on 2022-10-192022-11-15 Journal: Frontiers in Immunology [Category] 진단, [키워드] antibody Antigen autoantibodies autoantibody Autoimmune Autoimmune disease Autoimmune diseases binding Biomarker Cancer caused COVID COVID - 19 COVID-19 Diagnosis diagnostics disease Disease diagnosis disease-associated global pandemic Host include positive predict Prognosis self-antigens stability Symptom therapy Treatment [DOI] 10.3389/fimmu.2022.953726 PMC 바로가기
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancerArticle Published on 2022-10-182022-11-15 Journal: Cell Reports Medicine [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] addition Blood Blood cancer Breakthrough infection Cancer CAPTURE study COVID-19 COVID-19 vaccine Delta detectable dose greater immune response Infection Live virus marker microneutralization NAb titer NAbT Neutralizing Neutralizing antibodies Neutralizing antibody titer of BNT162b2 omicron Patient proportion risk SARS-CoV-2 SARS-CoV-2 variant severe COVID-19 disease T cell response T cells therapy vaccination vaccine dose variants of concern wild-type [DOI] 10.1016/j.xcrm.2022.100781 PMC 바로가기
The safety of esophageal cancer surgery during COVID-19Article Published on 2022-10-142022-11-16 Journal: Medicine [Category] meta-analysis, [키워드] 95% confidence interval anastomotic Blood Cancer Chinese Cochrane Library complications conducted coronavirus disease COVID-19 COVID-19 pandemic database determine evaluate Evidence Fang heterogeneity Hospital stay ICU identify Infrastructure intensive care journal mean difference Meta-analysis Mortality outcome outcomes pandemic Patient postoperative Primary outcome random effect model readmission Registered researchers risk risk ratio secondary outcome surgical systematic review Trial was performed Web of Science were used [DOI] 10.1097/MD.0000000000030929 PMC 바로가기
SARS-CoV-2 in immunocompromised individualsArticle Published on 2022-10-112022-11-15 Journal: Immunity [Category] COVID19(2023년), SARS, 치료제, [키워드] adaptive anti-CD20 antiviral immune response B cell Cancer clearance Combination COVID-19 COVID-19 pandemic Critical Hematologic malignancy Immunity Immunocompromised immunocompromised individual immunologically immunosuppressive IMPROVE increased risk individual Infection Inflammation information limit morbidity and mortality populations provided SARS-CoV-2 T cell therapy Treatment treatment strategy underlying conditions understanding vaccination viral infection virus [DOI] 10.1016/j.immuni.2022.09.006 PMC 바로가기